No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
Acetate |
Acetate |
- |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
2 |
Administration of a high dose of desipramine |
Desipramine |
D00812, D07791 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
1件: 156 |
3 |
Administration of a low dose of desipramine |
Desipramine |
D00812, D07791 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
1件: 156 |
4 |
Alpha-tocotrienol quinone |
Tocotrienol |
- |
- |
- |
1件: 156 |
5 |
Anavex2-73 |
- |
- |
- |
- |
2件: 6, 156 |
6 |
Creatine |
Creatine |
- |
- |
- |
12件: 1, 2, 5, 6, 8, 13, 46, 49, 50, 113, 156, 201 |
7 |
Creatine monohydrate |
Creatine |
- |
- |
- |
4件: 2, 8, 113, 156 |
8 |
Desipramine |
Desipramine |
D00812, D07791 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
2件: 120, 156 |
9 |
Dextromethorphan |
Dextromethorphan |
D00848, D03742, D03744 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
9件: 2, 6, 8, 13, 46, 78, 96, 97, 156 |
10 |
Donepezil |
Donepezil |
D00670, D07869 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
9件: 5, 6, 13, 46, 78, 124, 127, 156, 206 |
11 |
Donepezil hydrochloride |
Donepezil |
D00670, D07869 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
2件: 124, 156 |
12 |
Emd 128130 |
- |
- |
- |
- |
2件: 6, 156 |
13 |
Epi-743 |
- |
- |
- |
- |
2件: 21, 156 |
14 |
Fingolimod |
Fingolimod |
D10001 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
3件: 13, 14, 156 |
15 |
Fingolimod (fty720) |
Fingolimod |
D10001 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
2件: 13, 156 |
16 |
Glatiramer |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
4件: 2, 13, 96, 156 |
17 |
Glatiramer acetate |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
3件: 13, 96, 156 |
18 |
Glatiramer acetate (copaxone®) |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 156 |
19 |
Gwp42003-p |
- |
- |
- |
- |
5件: 140, 144, 145, 156, 158 |
20 |
Human insulin |
Insulin human |
D00085, D03230 |
1件: INSR |
20件: AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease (NAFLD), Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway |
2件: 96, 156 |
21 |
Ketamine |
Ketamine |
D00711, D08098 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
5件: 13, 70, 113, 156, 215 |
22 |
Lactobacillus plantarum |
Lactobacillus plantarum |
- |
- |
- |
2件: 6, 156 |
23 |
Lovastatin |
Lovastatin |
D00359 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
10件: 6, 34, 46, 79, 156, 160, 195, 206, 263, 310 |
24 |
Nnz-2566 |
- |
- |
- |
- |
2件: 156, 206 |
25 |
Probiotic-lactobacillus plantarum ps128 |
Lactobacillus plantarum |
- |
- |
- |
1件: 156 |
26 |
Recombinant human insulin growth factor 1 (rhigf-1) |
Insulin human |
D00085, D03230 |
1件: INSR |
20件: AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease (NAFLD), Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway |
1件: 156 |
27 |
Rhigf-1 |
- |
- |
- |
- |
1件: 156 |
28 |
Risperidone |
Risperidone |
D00426 |
2件: DRD2, HTR2A |
11件: Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, cAMP signaling pathway |
5件: 8, 156, 179, 187, 206 |
29 |
Sarizotan |
Sarizotan |
- |
- |
- |
2件: 6, 156 |
30 |
Sarizotan hydrochloride |
Sarizotan |
- |
- |
- |
2件: 6, 156 |
31 |
Tocotrienol |
Tocotrienol |
- |
- |
- |
2件: 156, 299 |
32 |
Topiramate |
Topiramate |
D00537 |
36件: CA2, CA4, CACNA1C, CACNA1D, CACNA1F, CACNA1S, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
48件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Arrhythmogenic right ventricular cardiomyopathy (ARVC), Bile secretion, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Collecting duct acid secretion, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term depression, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Nitrogen metabolism, Oxytocin signaling pathway, Pancreatic secretion, Proximal tubule bicarbonate reclamation, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Transcriptional misregulation in cancer, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
5件: 6, 140, 144, 156, 193 |
33 |
Tridecanoic acid |
- |
- |
- |
- |
1件: 156 |
34 |
Triheptanoin |
Triheptanoin |
D11465 |
- |
- |
10件: 2, 8, 120, 149, 156, 248, 256, 257, 317, 324 |